Table 6 The comparative analysis for GSA and the proposed method.
From: Discriminative biomarker selection using hybrid multi-population evolutionary computation
Datasets | Measures | GSA | Proposed | ||||
|---|---|---|---|---|---|---|---|
Best | Avg | Worse | Best | Avg | Worse | ||
Leukemia cancer | Acc | 95.25 | 88.25 | 80.51 | 97.85 | 87.31 | 82.52 |
#feat | 27 | 21 | 33 | 17 | 18 | 30 | |
MLL | Acc | 92.88 | 86.54 | 77.52 | 94.25 | 90.51 | 79.63 |
#feat | 21 | 28 | 39 | 18 | 19 | 24 | |
Ovarian | Acc | 91.78 | 84.65 | 77.63 | 96.75 | 88.67 | 79.32 |
#feat | 17 | 24 | 35 | 14 | 22 | 26 | |
CNS | Acc | 90.54 | 81.99 | 76.32 | 95.25 | 88.05 | 74.38 |
#feat | 24 | 38 | 44 | 18 | 26 | 34 | |
SRBCT | Acc | 99.25 | 88.07 | 94.52 | 100 | 94.25 | 92.56 |
#feat | 17 | 25 | 36 | 11 | 20 | 27 | |
Lung cancer | Acc | 97.71 | 94.63 | 86.52 | 100 | 95.36 | 87.25 |
#feat | 22 | 30 | 41 | 15 | 20 | 29 | |
